Renal transplantationRejection: DiagnosisUridine Diphosphate Glucuronosyltransferase 2B7 Variant p.His268Tyr as a Predictor of Kidney Allograft Early Acute Rejection
Section snippets
Patients and Methods
The study was approved by the local Ethics Committee at the Medical University of Warsaw and was conducted according to the approved protocols.
The prospective, historical cohort study of kidney transplant recipients included 235 patients who fulfilled the following criteria: given informed consent, availability of DNA sample, access to standard medical file, triple maintenance immunosuppression based on glucocoticosteroids, and MMF and either cyclosporine A or tacrolimus given from the day of
Results
The overall characteristics of the study population and the frequencies of UGT2B7 802C>T genotypes are given in Table 1. The observed distribution of CC, CT, and TT genotypes was consistent with the Hardy-Weinberg equilibrium (P = .22; χ2 = 1.49). On the crude analysis the presence of UGT2B7 802C>T allelic variants was insignificant for acute rejection risk, the incidence of myelosupression (leukopenia, granulocytopenia, lymphopenia, and thrombocytopenia), GI side effects, and infectious
Discussion
Our results show that in kidney transplant recipients the association between UGT2B7 802C>T polymorphism and acute rejection is limited to the early post-transplantation weeks. This observation confirms the results in stable thoracic organ recipients.1 Other authors who did not find such a relationship were analyzing a clinical course of kidney recipient populations over a period of 12 post-transplantation months.3, 4
UGT2B7 was identified as one of the major uridine
References (15)
- et al.
The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro
Clin Biochem
(2010) - et al.
Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?
Clin Biochem
(2000) - et al.
Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats
Biochimie
(2007) - et al.
Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study
Pharmacotherapy
(2010) - et al.
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients
Pharmacogenet Genomics
(2007) - et al.
SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients
Pharmacogenomics
(2010) - et al.
UGTlA9 −275T>A/−2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients
Clin Pharmacol Ther
(2009)
Cited by (9)
Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid
2022, European Journal of Clinical PharmacologyInfluence of slco1b1 521t>c, ugt2b7 802c>t and impdh1 −106g>a genetic polymorphisms on mycophenolic acid levels and adverse reactions in chinese autoimmune disease patients
2021, Pharmacogenomics and Personalized Medicine
This study was supported by grants from the Polish Ministry of Science and Higher Education N N402 4266 33 and Medical University of Warsaw 1M15/N/2010-2012.